Current Report: Elekta May Gain 19.3% This Year

The company was founded in 1972 and is headquartered in Stockholm, Sweden.

Elekta AB (EKTAF), as a medical technology company, provides clinical solutions for the treatment of cancers and brain disorders. 

Three key data points gauge EKTAF (or any dividend-paying entity):

(1) Price 

(2) Dividends

(3) Returns

Those three keys also indicate if any company has made, is making, and will make money.

EKTAF Price

Elekta single share price rose $0.90 (or about 20%) from $5.16 to $6.06 in the past year, per Friday’s morning market report.

No analysts cover the stock so one year price targets are not available.  However, the one year of price history shows that average  $0.90 price gain, which I’ll use to calculate returns after I discuss dividends.  

EKTAF Dividends

Elekta AB has paid quarterly dividends since September 2013.  The most recent Q dividend of $0.1352 was paid  March 11 (to shareholders on record as of March 6) for a $ $0.2704 forward annual dividend yielding 4.46% 

EKTAF Returns

Putting it all together, as of May 15 a possible gross gain of $1.1704 was projected. The $0.90 per share annual gain was added to the $0.2704 forward looking annual dividend.

A little under $1000 invested in EKTAF at Friday’s $6.06 opening share price would buy 165 shares which multiply the $1.1704 gross gain to $193.14 for the coming year, or 19.3%.

My dividend dogcatcher rule is to only buy initial shares of a dividend stock that pay an annual dividend (from $1000 invested) that is more than the cost of one share.

Elekta’s annual dividend from $1K invested is $44.50. So Elekta AB shows a dividend from $1,000 invested just over 7.33 times its $6.06 single share price of Friday.

The exact track of Elekta’s future share price and dividend will entirely be determined by market action and company finances. 

Remember, the best way to track stock performance and dividend payments is through direct ownership of company shares.